This is a snippet of the transcript, sign up to read more.
There are two points I'd like to make. Firstly, in terms of performance, while Essentra has indeed sold filters and packaging to become a pure play, I believe this is a rather simplistic approach. It implies a focus on their current operations, particularly as components are generating a significant portion of the group's profit. It makes sense to reinvest this profit back into components. However, the issue is that they are fundamentally supplying to industrial markets, leaving them exposed to macroeconomic effects. When other businesses were part of the group, there was a natural hedge against these macro effects. For instance, filters, which were sold to cigarette companies, were not impacted by recessionary effects. This provided some natural protection, which is now lost since the businesses have been split.
This is a snippet of the transcript, sign up to read more.
In my current role, when I evaluate assets, one of the questions I ask is, what does this business do when times get tough? This is a question I would pose to Essentra and RS as well. If you look at RS's recent results, they're showing exposure to end markets. When times get tough, they have a couple of options. They can spend more money on marketing. That's really the only option they have. They can increase marketing to try and pull more back in. They're not going to suddenly win a £300,000 contract because that's not their business model.
This is a snippet of the transcript, sign up to read more.
Perhaps 10%. I think it's a stretch to say that it's all critical. Some of their products, if they didn't supply them in time, could cause a line stop in automotive, for example. That's where I put the 10%. Critical could mean many things, but causing a line stop, I don't think, is critical.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research